Quick Answer
Date Sleep Quality Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Background Insomnia during pregnancy is a modifiable risk factor for depression.
Key Takeaways
- 01Background Insomnia during pregnancy is a modifiable risk factor for depression. [Felder JN (2026)]
- 02Research in nonpregnant populations and preliminary findings in a pregnant population suggest that targeting insomnia with digital cognitive behavioral therapy for insomnia (CBT-I) may prevent depression. [Felder JN (2026)]
- 034 5 6 7 8 8 9 In recent years, evidence-based guidelines have been developed to provide clinicians and patients with structured recommendations for managing the expanding spectrum of FMS treatment options []. [Demir Ceren (2026)]
- 04However, duloxetine treatment may be associated with adverse effects such as nausea, anxiety, insomnia, and diarrhea, which may negatively influence treatment adherence and overall patient well-being [,]. [Demir Ceren (2026)]
The current Migaku evidence database contains 2 reusable source documents for Date Sleep Quality Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Background Insomnia during pregnancy is a modifiable risk factor for depression. [Felder JN (2026); evidence level 2]
- Research in nonpregnant populations and preliminary findings in a pregnant population suggest that targeting insomnia with digital cognitive behavioral therapy for insomnia (CBT-I) may prevent depression. [Felder JN (2026); evidence level 2]
- 4 5 6 7 8 8 9 In recent years, evidence-based guidelines have been developed to provide clinicians and patients with structured recommendations for managing the expanding spectrum of FMS treatment options []. [Demir Ceren (2026); evidence level 2]
- However, duloxetine treatment may be associated with adverse effects such as nausea, anxiety, insomnia, and diarrhea, which may negatively influence treatment adherence and overall patient well-being [,]. [Demir Ceren (2026); evidence level 2]
- 4 6 10 11 12 13 14 Current guidelines consistently recommend a multimodal approach combining pharmacological and non-pharmacological strategies in the management of FMS [,,]. [Demir Ceren (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Digital Cognitive Behavioral Therapy for Insomnia Versus Sleep Hygiene Education for Prevention of Perinatal Depression: Protocol for a Randomized Clinical Trial.
- Home-based postural exercise as an adjunct to duloxetine improves sleep quality, physical quality of life, and trunk mobility in fibromyalgia: a randomized controlled trial